Search
Hepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnHepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form...
Drometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedDrometrizole trisiloxane is a photostable UVA and UVB light filter . The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved f...
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. The standard therapy for systemic lupus ery...
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a ...
Diet
go.drugbank.com/conditions/DBCOND0034841Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10596ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10597ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10600ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Texas/50/2012 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10776ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.